Another Coronavirus great news study from Israel

There’s been lots of worry, for obvious reasons, about how well coronavirus vaccines would work in people with immune disorders, such as people like me who have celiac disease, an auto-immune disorder (AID).

So the good news – actually, for a person with AID like me it’s great news – is that a study from Israel concluded that 86 % of the patients with an AID (in this study, all676 patients had rheumatic conditions such as lupus, ankylosing spondylitis, rheumatoid arthritis, and so on, but the finding should cover all AIDs) who participated in the study “developed sufficient antibodies to protect them from infection”.

Of equal importance, I think, the prevalence and seriousness of side effects among these patients were “similar to those in the general population”.

And what’s really important to point out here is that in the trials which Pfizer had conducted to find out whether their vaccine worked and how safe it was, no patients with autoimmune inflammatory rheumatic diseases or any other patients with suppressed immunity had been included (both for safety reasons and in order not to “skew the results”).

So this is really good “new” news, especially since many of these patients were on the kind of drugs that ordinarily tamp down the immune system – it’s the only way to control some of these conditions.